Gemma Montalban - Concepedia

Concepedia

Author

Gemma Montalban

Vall d'Hebron Institute of Oncology ORCID

Also Known As

G. Montalban, Gemma Montalban, M Montagna

32

Publications

1.1K

Citations

14

H-Index

31

Concepts

All Affiliations

Vall d'Hebron Institute of Oncology Vall d'Hebron Institut de Recerca Universitat Autònoma de Barcelona Vall d'Hebron Hospital Universitari Instituto de Investigación Sanitaria del Hospital Clínico San Carlos

GM

About

Gemma Montalban is an author at Vall d'Hebron Institute of Oncology specializing in medicine, breast cancer, and molecular diagnostics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	309
2	Public Health	4	4	210
3	Biostatistics	3	3	180
4	Epidemiology	1	1	148
5	Genetic Medicine	1	1	148

Gemma Montalban

×

16

Publications

1.1K

Citations

14

H-Index

	Year	Citations
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer Cristina Cruz, Marta Castroviejo‐Bermejo, Sara Gutiérrez‐Enríquez, Annals of Oncology	2018	410
Large scale multifactorial likelihood quantitative analysis of <i>BRCA1</i> and <i>BRCA2</i> variants: An ENIGMA resource to support clinical variant classification Michael T. Parsons, Emma Tudini, Hongyan Li, Human Mutation GeneticsGenetic EpidemiologyPathologyMultifactorial Likelihood AnalysisDisease Gene Identification	2019	148
Comparison of mRNA Splicing Assay Protocols across Multiple Laboratories: Recommendations for Best Practice in Standardized Clinical Testing Phillip J Whiley, Miguel de la Hoya, Mads Thomassen, Clinical Chemistry	2013	69
Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings Sandra Bonache, I. Esteban, Alejandro Moles‐Fernández, Journal of Cancer Research and Clinical Oncology Breast OncologyCancer RiskMultigene PanelMedicineClinical Actionability	2018	65
Computational Tools for Splicing Defect Prediction in Breast/Ovarian Cancer Genes: How Efficient Are They at Predicting RNA Alterations? Alejandro Moles‐Fernández, Laura Duran-Lozano, Gemma Montalban, Frontiers in Genetics	2018	64
A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor Amélie Rodrigue, Guillaume Margaillan, Thiago T. Gomes, Nucleic Acids Research	2019	55
Naturally occurring <i>BRCA2</i> alternative mRNA splicing events in clinically relevant samples James D. Fackenthal, Toshio F. Yoshimatsu, Bifeng Zhang, Journal of Medical Genetics	2016	52
Screening of <i>BRCA1/2</i> deep intronic regions by targeted gene sequencing identifies the first germline <i>BRCA1</i> variant causing pseudoexon activation in a patient with breast/ovarian cancer Gemma Montalban, Sandra Bonache, Alejandro Moles‐Fernández, Journal of Medical Genetics	2018	39
RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families Ana Blanco, Sara Gutiérrez‐Enríquez, Marta Santamariña, Breast Cancer Research and Treatment Breast OncologySomatic VariantRad51c Germline MutationsMedicineGenetics	2014	34
About 1% of the breast and ovarian Spanish families testing negative for <i>BRCA1</i> and <i>BRCA2</i> are carriers of <i>RAD51D</i> pathogenic variants Sara Gutiérrez‐Enríquez, Sandra Bonache, Gorka Ruíz de Garibay, International Journal of Cancer Genetic TestingGeneticsGenetic EpidemiologyPathologyMolecular Genetics	2013	30

Page 1